<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3246">
  <stage>Registered</stage>
  <submitdate>25/07/2011</submitdate>
  <approvaldate>25/07/2011</approvaldate>
  <nctid>NCT01403064</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects</studytitle>
    <scientifictitle>A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concomitant Chemotherapy and Radiotherapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ALD518-CLIN-009</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Oral Mucositis</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Head and neck</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - ALD518
Treatment: drugs - 0.9% saline

Experimental: Open Label ALD518 - 

Experimental: ALD518 Dose 1 - 

Experimental: ALD518 Dose 2 - 

Placebo Comparator: Placebo - 


Other interventions: ALD518
IV

Treatment: drugs: 0.9% saline
IV Infusion

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of ALD518, including incidence of adverse events, serious adverse events and clinically significant laboratory abnormalities</outcome>
      <timepoint>Participants will be followed for the duration of the trial, an expected average of 12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Clinically assessed ulcerative OM (Who Grade = 2) at a cumulative radiation dose of 55 Gy</outcome>
      <timepoint>The average time of this assessment will be 5-7 weeks after the initiation of RT</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary efficacy endpoint of OM assessments - Ulcerative (WHO Grade = 2) and severe (WHO Grade = 3) OM at cumulative doses of 35 Gy, 45 Gy, 55 Gy and 65 Gy; Duration of ulcerative and severe OM, Time of onset of ulcerative and severe OM</outcome>
      <timepoint>Measured from onset of OM through Week 4 Post-RT</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of ALD518 in plasma</outcome>
      <timepoint>Measured at Baseline, Week 2, Week 4, Last Day of RT and Week 4 Post-RT</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Impact of ALD518 on Patient-reported Outcomes as measured by the OMDQ, FACT-HN, and FACIT-fatigue scale</outcome>
      <timepoint>Begins at baseline and is measured at least weekly though WEek 4 Post-RT</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>C-reactive protein serum concentrations</outcome>
      <timepoint>Measured at intervals from Screening visit through Week 4 Post-RT</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have recently diagnosed (&lt; than 6 months prior to screening visit date),
             pathologically confirmed, non-metastatic SCC of the oral cavity, oropharynx,
             hypopharynx or larynx that will be treated with CRT as first-line treatment; subjects
             with a history of surgical management (approximately 4-6 weeks before RT with
             sufficient time for post-surgical healing) are eligible

          -  Have a plan to receive a continuous course of conventional external beam irradiation
             delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0
             to 2.2 Gy, with a cumulative radiation dose between 55 and 72 Gy.

          -  Have a plan to receive a standard cisplatin CT regimen administered tri-weekly (80 to
             100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2) or a standard carboplatin
             regimen administered weekly (100 mg/m2)

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status = 1

          -  CRP &lt; 80 mg/L

          -  Have adequate hematopoietic, hepatic, and renal function at the screening visit</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Tumor of the lips, sinuses, salivary glands, nasopharynx or unknown primary tumor

          -  Metastatic disease (M1) Stage IV C

          -  Any prior history of head and neck cancer

          -  Prior radiation to the head and neck

          -  Have had a major surgical procedure, other than for HNC, or significant traumatic
             injury within 4 weeks prior to the initiation of RT; or anticipation of need for a
             major surgical procedure during the clinical trial

          -  Active infectious disease, excluding oral candidiasis

          -  Have OM at the screening visit

          -  Have a history of hypersensitivity to monoclonal antibody</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>81</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA</recruitmentstate>
    <hospital>St. Vincent's Hospital - Darlinghurst</hospital>
    <hospital>Calvary Mater Newcastle - Waratah</hospital>
    <hospital>Royale Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Adelaide Radiotherapy Centre - Adelaide</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode> - Woolloongabba</postcode>
    <postcode>5037 - Adelaide</postcode>
    <postcode> - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Salzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Udine</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alder Biopharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and efficacy of ALD518 in modifying the
      course of oral mucositis in subjects with head and neck cancer receiving concomitant
      chemotherapy and radiotherapy</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01403064</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jeffrey Smith, MD FRCP</name>
      <address>Alder Biopharmaceuticals, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>